125 related articles for article (PubMed ID: 3947392)
21. Specific binding sites for 1-O-alkyl-sn-glyceryl-3-phosphorylcholine on intact human blood neutrophils.
Korth RM
Int Arch Allergy Immunol; 1997 Aug; 113(4):460-4. PubMed ID: 9250592
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of platelet-activating factor by rat alveolar macrophages: lyso-PAF as an obligatory intermediate in the formation of alkylarachidonoyl glycerophosphocholine species.
Robinson M; Snyder F
Biochim Biophys Acta; 1985 Oct; 837(1):52-6. PubMed ID: 4052436
[TBL] [Abstract][Full Text] [Related]
23. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
Komuro Y; Imanishi N; Uchida M; Morooka S
Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
[TBL] [Abstract][Full Text] [Related]
24. [3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes.
Marquis O; Robaut C; Cavero I
J Pharmacol Exp Ther; 1988 Feb; 244(2):709-15. PubMed ID: 2831350
[TBL] [Abstract][Full Text] [Related]
25. Delipidation of alpha 1-acid glycoprotein. Propranolol binding to this glycoprotein and its modification by extracted material and exogenous lipids.
Chauvelot-Moachon L; Tallet F; Durlach-Misteli C; Giroud JP
J Pharmacol Methods; 1988 Aug; 20(1):15-28. PubMed ID: 3411974
[TBL] [Abstract][Full Text] [Related]
26. Characterization of platelet-activating factor binding sites on uterine membranes from pregnant rabbits.
Kudolo GB; Harper MJ
Biol Reprod; 1989 Oct; 41(4):587-603. PubMed ID: 2559778
[TBL] [Abstract][Full Text] [Related]
27. Metabolism of platelet activating factor in lung.
Snyder F; Blank ML; Lee TC
Ann N Y Acad Sci; 1991; 629():168-75. PubMed ID: 1952548
[TBL] [Abstract][Full Text] [Related]
28. Non-enzymatic platelet-activating factor formation by acetylated proteins.
Thanou PG; Tsoukatos DC
FEBS Lett; 2004 Aug; 573(1-3):11-4. PubMed ID: 15327967
[TBL] [Abstract][Full Text] [Related]
29. [Binding of 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine (thrombocyte activating factor) by plasma components. Exchange of the thrombocyte activating factor between lipoproteins and thrombocytes].
Kulikov VI; Bergel'son LD
Biokhimiia; 1984 Aug; 49(8):1310-5. PubMed ID: 6093897
[TBL] [Abstract][Full Text] [Related]
30. Effects of alpha-1-acid glycoprotein administration on propranolol binding and beta blockade in rats.
Keyler DE; Pentel PR
Biochem Pharmacol; 1989 Apr; 38(7):1163-8. PubMed ID: 2539818
[TBL] [Abstract][Full Text] [Related]
31. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
Grigoriadis G; Stewart AG
Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
[TBL] [Abstract][Full Text] [Related]
32. [Incorporation of 1-0-alkyl-2-acetyl-sn-glycerol-3-phosphocholine into human plasma lipoproteins in vitro. Effect of the lecithin:cholesterol acyltransferase activity of plasma].
Kulikov VI; Muzia GI; Bergel'son LD
Biokhimiia; 1984 Sep; 49(9):1449-55. PubMed ID: 6542803
[TBL] [Abstract][Full Text] [Related]
33. Catabolism of platelet-activating factor and its acyl analog. Differentiation of the activities of lysophospholipase and platelet-activating-factor acetylhydrolase.
Aarsman AJ; Neys FW; Van den Bosch H
Eur J Biochem; 1991 Aug; 200(1):187-93. PubMed ID: 1879423
[TBL] [Abstract][Full Text] [Related]
34. Activation of guinea pig peritoneal macrophages by platelet activating factor (PAF) and its agonists.
Hayashi H; Kudo I; Inoue K; Onozaki K; Tsushima S; Nomura H; Nojima S
J Biochem; 1985 Jun; 97(6):1737-45. PubMed ID: 2993272
[TBL] [Abstract][Full Text] [Related]
35. Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein.
Ferry DG; Caplan NB; Cubeddu LX
J Pharm Sci; 1986 Feb; 75(2):146-9. PubMed ID: 2870173
[TBL] [Abstract][Full Text] [Related]
36. Alpha-1-acid glycoprotein concentrations and protein binding of propranolol in Sprague-Dawley and Dark Agouti rat strains treated by phenobarbital.
Chauvelot-Moachon L; Delers F; Poüs C; Engler R; Tallet F; Giroud JP
J Pharmacol Exp Ther; 1988 Mar; 244(3):1103-8. PubMed ID: 3252025
[TBL] [Abstract][Full Text] [Related]
37. Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein.
Abramson FP
Clin Pharmacol Ther; 1982 Nov; 32(5):652-8. PubMed ID: 7128006
[TBL] [Abstract][Full Text] [Related]
38. Stimulation of tumour necrosis factor release by cytotoxic analogues of platelet-activating factor.
Valone FH; Ruis NM
Immunology; 1992 May; 76(1):24-9. PubMed ID: 1628897
[TBL] [Abstract][Full Text] [Related]
39. Stereoselective binding of beta-blockers to purified rat alpha 1-acid glycoprotein.
Murai-Kushiya M; Okada S; Kimura T; Hasegawa R
J Pharm Pharmacol; 1993 Mar; 45(3):225-8. PubMed ID: 8097783
[TBL] [Abstract][Full Text] [Related]
40. Ether lysophospholipid-induced production of platelet-activating factor in human polymorphonuclear leukocytes.
Sugiura T; Fukuda T; Masuzawa Y; Waku K
Biochim Biophys Acta; 1990 Dec; 1047(3):223-32. PubMed ID: 2123719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
